Clinical Trials Logo

Clinical Trial Summary

Background: The removal of Laryngeal Mask Airway (LMA) in children may be associated with respiratory adverse events. The incidence of these adverse events may be influenced by the type of anesthesia maintenance. It is not clear whether Total Intravenous Anesthesia (TIVA) with propofol is associated with a lower incidence of respiratory events upon removal of LMA as compared to maintenance with sevoflurane. Specific Aim: The primary aim of this study is to compare the prevalence of respiratory adverse events following LMA removal in patient receiving TIVA versus sevoflurane inhalational anesthesia in a pediatric population aged between 6 month and 6 years old. Secondary outcomes include quality of induction, maintenance and emergence from anesthesia between the 2 groups as evidenced by ease of LMA insertion, absence of bucking or movement during the procedure, time to LMA removal, and absence of emergence agitation. Methods: In this prospective randomized clinical trial, children will be enrolled in one of two groups: Group 1 will receive propofol for induction and maintenance of anesthesia, Group 2 will receive sevoflurane for induction and maintenance of anesthesia. In both groups patients will be mechanically ventilated. At the end of the procedure, LMAs will be removed when patients are fully awake as defined by the return of reflexes, eye opening, and purposeful movements. Significance: Data comparing the influence of TIVA and sevoflurane on the occurrence of respiratory adverse events after LMA removal are limited. Both techniques are standard of care at our institution. However, as per our clinical observations, we hypothesize that TIVA is superior to sevoflurane. This study will identify the technique that provides optimal anesthetic conditions and improved patient's safety.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT03553082
Study type Interventional
Source American University of Beirut Medical Center
Contact
Status Completed
Phase N/A
Start date May 18, 2018
Completion date May 28, 2021

See also
  Status Clinical Trial Phase
Completed NCT02141412 - Intravenous Dexmedetomidine For The Quaity Of Emergence From General Anesthesia Phase 4
Completed NCT02375217 - "Low Dose Sugammadex Combined With Neostigmine and Glycopyrrolate Versus Full Dose Sugammadex for Reversal of Rocuronium-induced Neuromuscular Blockade: a Cost Saving Strategy" Phase 4
Recruiting NCT03200964 - OS Anesthesia Followup of All Bariatric Procedures at One Hospital
Recruiting NCT06334939 - Bispectral Index, Suppression Rate and Emergence Agitation in Spine Surgeries